Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Upwork Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while Upwork Inc trades at $8.58 (market cap $1.05B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 4.8× Upwork Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Upwork Inc for 38 Days on average.
| TVTX | UPWK | |
|---|---|---|
Market Cap | $5.02B | $1.05B |
Volume | 2,060,842 | 2,045,666 |
Sector | Health | Industrials |
52-Week High | $67.52 | $22.11 |
52-Week Low | $26.79 | $7.84 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $5.15B | $815.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UPWK trades at $8.64, up 0.35% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, though revenue guidance disappointed. Fundamentals show strong profitability with a 77.21% gross margin and 12.93% net margin, while valuation ratios like P/E of 11.08 and P/S of 1.49 appear reasonable. Recent news includes insider sales and a securities fraud investigation, adding uncertainty.
The outlook is mixed: analyst consensus is a Buy with a $9.64 price target, implying upside, but risks from AI disruption and legal issues persist. Earnings growth and cost management are key catalysts, though competitive pressures and volatile cash flows warrant caution for investors seeking exposure to the freelance marketplace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
